DSID,AU,TI,JR,PY,VL,IS,PG,AB,SA,REGID,STD.IND,STD.DESIGN,STD.GEO.LOCATION,STD.PHASE,ARM.NUM,ARM.BLIND,ARM.RANDFLG,ARM.TRT,ARM.TRTCLASS,ARM.DOSE,ARM.DOSEU,ARM.ROUTE,ARM.REGIMEN,ARM.FORMULATION,N.STUDY,N.ARM,N.ARM.STATANAL,N.ARM.EVENT.SUBJ,STATANAL.POP,STATANAL.METHOD,STATANAL.IMP.METHOD,ARM.TIME1,ARM.TIME1U,ENDPOINT,BSL.STAT,BSL.VAL,BSL.VALU,BSL.VAR,BSL.VARU,BSL.LCI,BSL.UCI,CHBSL.STAT,CHBSL.VAL,CHBSL.VALU,CHBSL.VAR,CHBSL.VARU,CHBSL.LCI,CHBSL.UCI,RSP.STAT,RSP.VAL,RSP.VALU,RSP.VAR,RSP.VARU,RSP.LCI,RSP.UCI,PCHBSL.STAT,PCHBSL.VAL,PCHBSL.VAR,PCHBSL.VARU,PCHBSL.LCI,PCHBSL.UCI,ARM.PCT.MALE,ARM.AGE,ARM.AGEU
432,Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S,Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin,DIABETES.OBES.METAB,2012,14,6.0,539~545,,CR014881,NCT01177163,T2D;Obesity,Sequential,US,Phase 1b,0.0,Double-Blind,True,placebo,Placebo,0,MG/DAY,SC,,,29,7.0,7,,CO,,,0.0,WK,HbA1c,Mean,7.99,percent,0.52,SD,,,Mean,0.0,percent,,,,,Mean,7.99,percent,0.52,SD,,,Mean,0.0,,,,,56.0,52.8,YR
432,Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S,Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin,DIABETES.OBES.METAB,2012,14,6.0,539~545,,CR014881,NCT01177163,T2D;Obesity,Sequential,US,Phase 1b,0.0,Double-Blind,True,placebo,Placebo,0,MG/DAY,SC,,,29,7.0,7,,CO,,,3.8571429,WK,HbA1c,Mean,7.99,percent,0.52,SD,,,Mean,-0.19,percent,0.49,SD,-0.628,0.248,Mean,7.8,percent,,,,,Mean,-2.378,,,,,56.0,52.8,YR
432,Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S,Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin,DIABETES.OBES.METAB,2012,14,6.0,539~545,,CR014881,NCT01177163,T2D;Obesity,Sequential,US,Phase 1b,1.0,Double-Blind,True,canagliflozin,SGLT2,100,MG/DAY,SC,QAM,,29,10.0,10,,CO,,,0.0,WK,HbA1c,Mean,8.38,percent,0.88,SD,,,Mean,0.0,percent,,,,,Mean,8.38,percent,0.88,SD,,,Mean,0.0,,,,,70.0,50.5,YR
432,Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S,Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin,DIABETES.OBES.METAB,2012,14,6.0,539~545,,CR014881,NCT01177163,T2D;Obesity,Sequential,US,Phase 1b,1.0,Double-Blind,True,canagliflozin,SGLT2,100,MG/DAY,SC,QAM,,29,10.0,10,,CO,,,3.8571429,WK,HbA1c,Mean,8.38,percent,0.88,SD,,,Mean,-0.73,percent,0.5,SD,-1.082,-0.378,Mean,7.65,percent,,,,,Mean,-8.711,,,,,70.0,50.5,YR
432,Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S,Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin,DIABETES.OBES.METAB,2012,14,6.0,539~545,,CR014881,NCT01177163,T2D;Obesity,Sequential,US,Phase 1b,2.0,Double-Blind,True,canagliflozin,SGLT2,600,MG/DAY,SC,BID,,29,10.0,10,,CO,,,0.0,WK,HbA1c,Mean,8.42,percent,1.02,SD,,,Mean,0.0,percent,,,,,Mean,8.42,percent,1.02,SD,,,Mean,0.0,,,,,30.0,42.7,YR
432,Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S,Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin,DIABETES.OBES.METAB,2012,14,6.0,539~545,,CR014881,NCT01177163,T2D;Obesity,Sequential,US,Phase 1b,2.0,Double-Blind,True,canagliflozin,SGLT2,600,MG/DAY,SC,BID,,29,10.0,10,,CO,,,3.8571429,WK,HbA1c,Mean,8.42,percent,1.02,SD,,,Mean,-0.92,percent,0.66,SD,-1.385,-0.455,Mean,7.5,percent,,,,,Mean,-10.926,,,,,30.0,42.7,YR
